Vanguard Group Inc. Increases Position in Elanco Animal Health Incorporated $ELAN

Vanguard Group Inc. increased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,586,708 shares of the company’s stock after purchasing an additional 759,623 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Elanco Animal Health worth $978,536,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. grew its stake in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares during the last quarter. Fifth Third Bancorp grew its position in shares of Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after buying an additional 2,807 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its stake in shares of Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after acquiring an additional 2,414 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN opened at $24.96 on Friday. The firm has a market capitalization of $12.40 billion, a PE ratio of 416.09, a price-to-earnings-growth ratio of 3.73 and a beta of 1.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $26.08. The company’s fifty day moving average price is $23.84 and its 200-day moving average price is $21.44.

Insider Transactions at Elanco Animal Health

In other news, CFO Robert M. Vanhimbergen purchased 6,950 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the purchase, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. This trade represents a 5.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev A. Modi acquired 4,500 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the acquisition, the insider directly owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. This trade represents a 3.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. boosted their target price on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday. Morgan Stanley upped their target price on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, December 18th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $25.89.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.